The estimated Net Worth of James Fox is at least $2.22 Milion dollars as of 6 March 2020. James Fox owns over 9,000 units of GenMark Diagnostics Inc stock worth over $1,949,283 and over the last 14 years he sold GNMK stock worth over $0. In addition, he makes $266,184 as Non-Executive Independent Director at GenMark Diagnostics Inc.
James has made over 3 trades of the GenMark Diagnostics Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he bought 9,000 units of GNMK stock worth $49,500 on 6 March 2020.
The largest trade he's ever made was buying 23,810 units of GenMark Diagnostics Inc stock on 26 June 2012 worth over $100,002. On average, James trades about 2,801 units every 176 days since 2010. As of 6 March 2020 he still owns at least 81,085 units of GenMark Diagnostics Inc stock.
You can see the complete history of James Fox stock trades at the bottom of the page.
Dr. James Charles Fox Ph.D. serves as Non-Executive Independent Director of the Company. Dr. Fox served as our Chair of the Board from August 2014 to February 2020 and continues to serve on our Board as a non-executive director. Dr. Fox has extensive experience in global technology and healthcare businesses. Dr. Fox led the start-up of Invetech, an Australian contract research and development company that specializes in healthcare products and complex instruments for international markets. Invetech was merged with Australian Securities Exchange listed Vision Systems Limited in 1993, and Dr. Fox took over as Group Managing Director of the combined entity. In January 2007, Vision Systems Ltd., then a global cancer diagnostics company, was acquired by Danaher Corporation. Prior to Invetech, Dr. Fox spent seven years working as a consultant and director with PA Technology. Dr. Fox currently serves as a director of TTP Group plc, a privately held company. Dr. Fox retired from the board of directors of Air New Zealand Ltd. in August 2014 after nearly eight years of service and retired from the board of directors of Biota Pharmaceuticals Inc. in November 2015 after nearly seven years as Chairman and Lead Director. Dr. Fox retired from the Board of Directors of Novasyte, LLC, a privately held company, following the company’s acquisition by IQVIA in March 2019. Dr. Fox received his Bachelor’s, Master’s and Ph.D. degrees in engineering from the University of Melbourne. Fox is qualified to serve as on our Board based on his executive experience in the medical device and molecular diagnostics industries as described above.
As the Non-Executive Independent Director of GenMark Diagnostics Inc, the total compensation of James Fox at GenMark Diagnostics Inc is $266,184. There are 4 executives at GenMark Diagnostics Inc getting paid more, with Scott Mendel having the highest compensation of $1,749,300.
James Fox is 68, he's been the Non-Executive Independent Director of GenMark Diagnostics Inc since 2020. There are 1 older and 8 younger executives at GenMark Diagnostics Inc. The oldest executive at GenMark Diagnostics Inc is Daryl Faulkner, 71, who is the Independent Director.
Over the last 14 years, insiders at GenMark Diagnostics Inc have traded over $27,572,889 worth of GenMark Diagnostics Inc stock and bought 454,838 units worth $2,182,328 . The most active insiders traders include Hany Massarany, Jon Faiz Kayyem oraz Kevin C Oboyle. On average, GenMark Diagnostics Inc executives and independent directors trade stock every 5 days with the average trade being worth of $141,403. The most recent stock trade was executed by Michael Gleeson on 14 April 2021, trading 27,667 units of GNMK stock currently worth $326,471.
GenMark Diagnostics Inc executives and other stock owners filed with the SEC include: